A New Prestigious Scientific Publication for Carbios Marks the Expansion of Its Research to Other Plastics
Regulatory News:
Carbios (Euronext Growth Paris: ALCRB) (Paris:ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastics and textiles, announces the publication of an article entitled "Enzymes' power for plastics degradation" in Chemical Reviews, one of the 10 most influential scientific journals in the world. The article is a comprehensive and critical review of research published to date on the enzymatic degradation of all types of plastics (PET, PLA, polyolefins, polyurethanes, polyamides) and includes almost 700 references. Co-authored by biotechnology researchers from Carbios and its academic partner Toulouse Biotechnology Institute (TBI), as well as two eminent professors in polymer science from the University of Bordeaux, the work brings together expertise in the fields of enzymology, polymer science and industry in order to accelerate the transition to a circular economy for plastic.
Beyond the comprehensive bibliographical study, the authors analyzed the data to discuss the scope, limitations, challenges and opportunities of enzymatic plastic recycling with a view to developing innovations and industrial processes. The article’s unique standpoint and added value with regard to issues surrounding plastic pollution is its critical view on technology transfer and industrial scalability.
"Any new scientific research project begins with an exhaustive bibliographical study, as we did for our PET biorecycling and PLA biodegradation technologies. Today, Carbios is the most advanced company in the industrialization of its PET biorecycling technology," commented Alain Marty, Chief Scientific Officer at Carbios. "Carbios' mission is to bring all types of plastics into the circular economy. I am therefore very proud to have collaborated with our long-term partner TBI, as well as with new partners at the University of Bordeaux, on the article published in Chemical Reviews which will serve as the basis for research into biological recycling solutions for other polymers.”
"Following the invitation to write an article for the upcoming Thematic Issue of Chemical Reviews, we collaborated once more with Carbios. In line with the subject 'Bridging the Gaps: Learning from Catalysis across Boundaries', our collaboration goes beyond the boundaries of plastics and polymer science in order to consider industrial feasibility, and find new solutions for different polymers using biocatalysis," said Isabelle André, Research Director at CNRS . "As a researcher, it is always gratifying and rewarding to see the fruit of hard work published in a prestigious journal, and I congratulate all the researchers involved.”
To read the article in Chemical Reviews, click here : https://pubs.acs.org/doi/10.1021/acs.chemrev.2c00644
Publication has been scheduled for the upcoming Thematic Issue “Bridging the Gaps: Learning from Catalysis across Boundaries”.
Author(s): Tournier, Vincent (Carbios) ; Duquesne, Sophie (TBI) ; Guillamot, Frédérique (Carbios) ; Cramail, Henri (Université Bordeaux); Taton, Daniel (Université Bordeaux); Marty, Alain (Carbios); André, Isabelle (TBI)
About Carbios
Established in 2011 by Truffle Capital, Carbios is a green chemistry company, developing biological and innovative processes. Through its unique approach of combining enzymes and plastics, Carbios aims to address new consumer expectations and the challenges of a broad ecological transition by taking up a major challenge of our time: plastic and textile pollution. Carbios deconstructs any type of PET (the dominant polymer in bottles, trays, textiles made of polyester) into its basic components which can then be reused to produce new PET plastics with equivalent quality to virgin ones. This PET innovation, the first of its kind in the world, was recently recognized in a scientific paper published on the front cover of the prestigious journal Nature. Carbios successfully started up its demonstration plant in Clermont-Ferrand in 2021. It has now taken another key step towards the industrialization of its process with the construction of a first-of-a-kind unit in partnership with Indorama Ventures.
In 2017, Carbios and L’Oréal co-founded a consortium to contribute to the industrialization of its proprietary recycling technology. Committed to developing innovative solutions for sustainable development, Nestlé Waters, PepsiCo and Suntory Beverage & Food Europe joined this consortium in April 2019. In 2022, Carbios signed an agreement with On, Patagonia, PUMA, and Salomon, to develop solutions promoting the recyclability and circularity of their products. PVH Corp. joined this consortium in January 2023.
The Company has also developed an enzymatic biodegradation technology for PLA-based (a bio sourced polymer) single-use plastics. This technology can create a new generation of plastics that are 100% compostable in domestic conditions, integrating enzymes at the heart of the plastic product.
For more information, please visit www.carbios.com/en / Twitter: Carbios LinkedIn: Carbios Instagram: insidecarbios
Carbios (ISIN FR0011648716/ALCRB) is eligible for the PEA-PME, a government program allowing French residents investing in SMEs to benefit from income tax rebates.
Translation is for information purposes only.
In case of discrepancy between the French and the English version of this press release, the French version shall prevail
1 Toulouse Biotechnology Institute, joint research unit associating INSA of Toulouse, CNRS and INRAE
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230321005849/en/
Contact information
CARBIOS
Melissa Flauraud
Press Relations
melissa.flauraud@carbios.com
Benjamin Audebert
Investor Relations
contact@carbios.com
+33 (0)4 73 86 51 76
Press Relations (Europe)
Iconic
Marie-Virginie Klein
mvk@iconic-conseil.com
+33 (0)1 44 14 99 96
Press Relations (U.S.)
Rooney Partners
Kate L. Barrette
kbarrette@rooneyco.com
+1 212 223 0561
Press Relations (DACH)
MC Services
Anne Hennecke
carbios@mc-services.eu
+49 (0)211 529 252 22
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Global Adds González-Paullada Domínguez in Monterrey, Mexico7.1.2026 16:30:00 EET | Press release
Andersen Global broadens its Latin American platform through a Collaboration Agreement with Monterrey-based law firm González-Paullada Domínguez (GPD), further strengthening the organization’s coverage in Mexico. Founded in 2021, GPD offers comprehensive services across transactional and litigation matters. The firm advises clients across sectors—including manufacturing, real estate, insurance, information technology, mining, and banking—on corporate law, mergers and acquisitions, real estate transactions, foreign investment, commercial contracts, regulatory compliance, and ongoing legal audits. GPD also represents clients in complex civil and commercial litigation, arbitration, and insolvency proceedings. “Monterrey is a major economic hub where local credibility and deep relationships are essential, particularly for foreign investors seeking to enter the market,” said Alfonso González-Paullada Guerrero, founder and managing partner of GPD. “By collaborating with Andersen Global, we s
1NCE Continues Growth and Expands Its Software, AI and Services Offering7.1.2026 15:15:00 EET | Press release
1NCE, a company offering a plug-and-play platform for creating and managing the world’s best IoT products, reports another strong growth year, adding another 10 million endpoints. The company now manages 40+ million intelligent products for 30,000+ customers across 17 industries. 1NCE’s software and connectivity platform has become a new industry standard, delivering hassle-free IoT in 170+ countries and regions. The company has a unique vantage point in the IoT ecosystem, with four billion data records per day collected through 250+ streams on the world’s largest IoT network in the cloud. The company launched a new intelligent data program called 1NCE Insights. The program is part of the company’s goal of fusing AI + IoT intelligence to drive game-changing results in supply chains, smart cities, utilities and beyond. Customer-collected data is theirs and theirs alone. But with Insights, 1NCE opens access to its anonymized, networkwide data. Customers can benchmark their IoT projects a
Prudentia Sciences Announces Series A Led by McKesson Ventures, Accelerating Due Diligence for Life Sciences Dealmaking7.1.2026 15:00:00 EET | Press release
Prudentia Sciences, a pioneer in AI-native due diligence for life sciences dealmaking, today announced that it has secured $20 million in Series A financing. The round was led by McKesson Ventures with participation from SignalFire. Existing investors include Iaso Ventures, Virtue and GV. This brings the company’s total funding to $27 million, following a $7 million seed round in 2024. Prudentia Sciences provides an AI-native platform that enables pharma companies, biotechs, and financial institutions to evaluate breakthrough medicines with unprecedented speed and rigor. By synthesizing complex clinical signals into actionable insights, Prudentia accelerates deal throughput and provides strategic leverage for acquisition, licensing, or investment decisions made by business development, investment, and diligence teams. The company’s human-in-the-loop approach orchestrates seamless collaboration between buyers, sellers, and intermediaries. This ensures a secure, compliant infrastructure
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations for treatment-resistant depression (TRD) from 10:00-11:30 am ET on January 7th. “PTSD is one of the most challenging mental health conditions, with approximately 13 million adults in the U.S. living with persistent symptoms and limited treatment options,” said Dr. Guy Goodwin, Chief Medical Officer at Compass Pathways. “We are pleased to advance our clinical development - the unmet need is profound, and it demands bold innovation. We believe COMP360 has the potential to tra
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom